Table 3.
Secondary Analysis by Intervention Group: MCIDs for Two Measures of Cognitive Function
| # RCTs (# Participants) |
SD Range | Pooled SD | MCID: 0.4 x SD |
MCID: 0.5 x SD |
|
|---|---|---|---|---|---|
| Donepezil | |||||
| MMSE | |||||
| Baseline SDs | 35 (3785) | 1.08 to 5.90 | 4.2 | 1.7 | 2.1 |
| Mean Change SDs | 28 (3125) | 0.33 to 6.12 | 3.6 | 1.4 | 1.8 |
| ADAS-Cog | |||||
| Baseline SDs | 22 (1693) | 6.56 to 15.8 | 10.2 | 4.1 | 5.1 |
| Mean Change SDs | 20 (2215) | 3.96 to 7.46 | 5.8 | 2.3 | 2.9 |
| Galantamine | |||||
| MMSE | |||||
| Baseline SDs | 7 (1285) | 1.92 to 4.12 | 3.9 | 1.6 | 2.0 |
| Mean Change SDs | 5 (1102) | 2.24 to 4.05 | 3.9 | 1.6 | 2.0 |
| ADAS-Cog | |||||
| Baseline SDs | 16 (2296) | 5.02 to 11.78 | 9.7 | 3.9 | 4.9 |
| Mean Change SDs | 22 (3179) | 5.00 to 7.43 | 6.0 | 2.4 | 3.0 |
| Rivastigmine | |||||
| MMSE | |||||
| Baseline SDs | 17 (1944) | 0.98 to 4.9 | 3.5 | 1.4 | 1.8 |
| Mean Change SDs | 12 (1891) | 0.46 to 3.6 | 3.2 | 1.3 | 1.6 |
| ADAS-Cog | |||||
| Baseline SDs | 14 (1825) | 4.60 to 12.30 | 10.0 | 4.0 | 5.0 |
| Mean Change SDs | 15 (2892) | 1.32 to 12.85 | 7.1 | 2.8 | 3.6 |
| Memantine | |||||
| MMSE | |||||
| Baseline SDs | 9 (548) | 1.60 to 6.20 | 4.0 | 1.6 | 2.0 |
| Mean Change SDs | 4 (442) | 2.20 to 5.65 | 4.1 | 1.6 | 2.1 |
| ADAS-Cog | |||||
| Baseline SDs | 5 (706) | 7.90 to 11.01 | 10.0 | 4.0 | 5.0 |
| Mean Change SDs | 3 (603) | 5.46 to 9.77 | 8.2 | 3.3 | 4.1 |
| Placebo | |||||
| MMSE | |||||
| Baseline SDs | 36 (4396) | 0.94 to 6.8 | 4.1 | 1.6 | 2.1 |
| Mean Change SDs | 27 (3758) | 0.33 to 5.76 | 3.7 | 1.5 | 1.9 |
| ADAS-Cog | |||||
| Baseline SDs | 28 (3398) | 2.55 to 17.3 | 10.1 | 4.1 | 5.1 |
| Mean Change SDs | 29 (4315) | 2.50 to 8.19 | 6.3 | 2.5 | 3.2 |
Abbreviations: Alzheimer Disease Assessment Scale – Cognitive Subscale (ADAS-Cog), minimum clinically important difference (MCID), Mini-Mental State Exam (MMSE), randomized trial (RCT), standard deviation (SD), number (#)